Holen Sie sich die Stockscreener-App
33.15
2.50%
0.81
Supernus Pharmaceuticals Inc Aktie (SUPN) Neueste Nachrichten
Millennium Management LLC Trims Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus at Jefferies Global Healthcare Conference: Strategic Insights By Investing.com - Investing.com South Africa
(SUPN) Trading Report - news.stocktradersdaily.com
Supernus at Jefferies Global Healthcare Conference: Strategic Insights - Investing.com
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Nuveen Asset Management LLC - Defense World
Supernus (SUPN) Partners with Jay Glazer for ADHD Awareness Series | SUPN Stock News - GuruFocus
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and R - GuruFocus
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals | SUPN Stock News - GuruFocus
Supernus Pharmaceuticals Partners with Jay Glazer for ADHD Awareness Series Featuring Insights from His Journey with Qelbree - Nasdaq
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD - GlobeNewswire
Jay Glazer and Wife Share Raw ADHD Story: How Treatment Changed Their Marriage - Stock Titan
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference - GlobeNewswire
Supernus (SUPN) to Protect Qelbree Patents Amid Generic Challenges | SUPN Stock News - GuruFocus
Supernus Pharmaceuticals Faces Patent Challenges for Qelbree - TipRanks
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference | SUPN Stock News - GuruFocus
Supernus CEO Fireside Chat: Latest CNS Pipeline Insights Coming at Major Healthcare Conference - Stock Titan
Supernus Announces Paragraph IV ANDA Filings for Qelbree® | SUPN Stock News - GuruFocus
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Increases Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
(SUPN) Investment Report - news.stocktradersdaily.com
Bank of America Corp DE Has $13.49 Million Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Busy Philipps Empowers Women with ADHD to Go from Feeling Misrep - GuruFocus
Busy Philipps Partners with Supernus (SUPN) to Empower Women wit - GuruFocus
Supernus Pharmaceuticals Partners with Busy Philipps for "Ms. Represented" Campaign to Empower Women with ADHD - Nasdaq
Busy Philipps Empowers Women with ADHD to Go from Feeling - GlobeNewswire
Busy Philipps Reveals ADHD Journey: New Campaign Spotlights Hidden Women's Symptoms - Stock Titan
Busy Philipps Empowers Women with ADHD to Go from Feeling Misrepresented to Being 'Ms. Represented' in First-of-its-Kind Campaign with Supernus Pharmaceuticals - The Manila Times
Supernus Pharmaceuticals (NASDAQ:SUPN) Raised to “Strong-Buy” at StockNews.com - Defense World
The Manufacturers Life Insurance Company Sells 797 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals (SUPN) Stock? - Nasdaq
Shareholders Can Be Confident That Supernus Pharmaceuticals' (NASDAQ:SUPN) Earnings Are High Quality - simplywall.st
Solid Earnings Reflect Supernus Pharmaceuticals' (NASDAQ:SUPN) Strength As A Business - Yahoo Finance
Supernus Pharmaceuticals (SUPN) to Release Quarterly Earnings on Wednesday - Defense World
SUPN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Supernus Pharmaceuticals, Inc. investment - ACCESS Newswire
Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by StockNews.com - Defense World
Supernus projects $600M-$630M revenue for 2025 with robust growth in core products - MSN
Lost Money on Supernus Pharmaceuticals, Inc. (SUPN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire
Stock Surge: Supernus Pharmaceuticals Inc (SUPN) Closes at 30.94, Marking a -4.59 Increase/Decrease - DWinneX
Levi & Korsinsky Reminds Supernus Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsSUPN - ACCESS Newswire
Supernus Pharmaceuticals First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by First Trust Advisors LP - Defense World
SUPN STOCK ALERT: Levi & Korsinsky Notifies Supernus Pharmaceuticals, Inc. Investors of an Ongoing Investigation - ACCESS Newswire
Earnings call transcript: Supernus Q1 2025 earnings miss expectations By Investing.com - Investing.com Canada
Supernus Pharmaceuticals Inc (SUPN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... - Yahoo Finance
Supernus Pharmaceuticals Inc (SUPN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... By GuruFocus - Investing.com Canada
Supernus Pharmaceuticals Inc (SUPN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges - GuruFocus
Supernus: Q1 Earnings Snapshot - CTPost
Decoding Supernus Pharmaceuticals Inc (SUPN): A Strategic SWOT I - GuruFocus
Earnings call transcript: Supernus Q1 2025 earnings miss expectations - Investing.com
Supernus Pharmaceuticals Q1 2025 Earnings: Revenue Surpasses Est - GuruFocus
SUPN Reports Higher than Expected Q1 Revenue at $149.8M | SUPN S - GuruFocus
Supernus Announces First Quarter 2025 Financial Results | SUPN S - GuruFocus
Supernus (SUPN) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Supernus Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q1 Sales Beat Estimates But Full-Year Sales Guidance Misses Expectations - Yahoo Finance
Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Surpass Estimates - Yahoo Finance
3.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):